Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798276 | 0.84 | PARP1 (0.57) | PARP1PDE10APARP2MAPTTNKS2 | |
| SCHEMBL6790215 | 0.81 | PARP1 (0.54) | PARP1PDE10APARP2MAPTTNKS2 | |
| SCHEMBL6795593 | 0.79 | PARP1 (0.64) | PARP1PDE10APARP2LMNATNKS2 | |
| Hydrochloric Acid SCHEMBL6789135 | 0.79 | PDE10A (0.70) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL6798298 | 0.79 | PARP1 (0.60) | PARP1PDE10APARP2MAPTTNKS2 | |
| SCHEMBL6795464 | 0.78 | PARP1 (0.63) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL6795780 | 0.77 | PARP1 (0.61) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL6791743 | 0.76 | PARP1 (0.54) | PARP1PDE10APARP2KDM4ELMNA | |
| SCHEMBL23073611 | 0.75 | PARP1 (0.73) | PARP1PDE10APARP2KDM4ELMNA | |
| SCHEMBL16404338 | 0.74 | PDE10A (0.84) | PARP1PDE10APARP2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885PDE10A 2013/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.